Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined.
Data on 1392 mRCC patients using pazopanib or sunitinib were pooled from two Phase-III clinical trials. Risk factors and prognostic effect of on-therapy proteinuria were evaluated by Cox proportional hazards regression.
Any-grade (1-4) and grade 3/4 proteinuria incidence were 15.0% and 3.7%, respectively. Asian ethnicity, diabetes, baseline systolic blood pressure (SBP), pre-existing grade 1 proteinuria and prior nephrectomy were significant independent predictors of either any-grade or grade 3/4 proteinuria. Proteinuria, particularly grade 3/4 (adjusted hazard ratio 0.53 (95% confidence interval 0.30-0.92)), was associated with improved overall survival.
In mRCC patients using pazopanib or sunitinib, Asian ethnicity, diabetes, SBP, pre-existing proteinuria and prior nephrectomy were independent predictors of on-therapy proteinuria, which was associated with improved survival.British Journal of Cancer advance online publication, 26 May 2016; doi:10.1038/bjc.2016.147 www.bjcancer.com.
British journal of cancer. 2016 May 26 [Epub ahead of print]
Michael J Sorich, Andrew Rowland, Ganessan Kichenadasse, Richard J Woodman, Arduino A Mangoni
Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia., Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia., Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia., Flinders Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia., Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.